Article
Biochemistry & Molecular Biology
Giulio Fortuna, Elena Calabria, Massimo Aria, Amerigo Giudice, Michele Davide Mignogna
Summary: In patients with oral-pharyngeal pemphigus vulgaris (OPV), B-cell depletion adjuvant therapy significantly impacts anti-Dsg-3 titer and B and T-cell lymphocyte subpopulations profile.
Article
Immunology
Zeinab Aryanian, Kamran Balighi, Maryam Daneshpazhooh, Emad Karamshahi, Parvaneh Hatami, Azadeh Goodarzi, Mahroo Tajalli, Terrence M. Vance
Summary: The study compared the side effect profiles of rituximab in two treatment strategies for pemphigus patients, and found that early use of rituximab is beneficial for certain patients, especially those with mucocutaneous phenotype, pulmonary comorbidity, or smoking history.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Dermatology
V. Maione, L. Bettolini, C. Cozzi, S. Bighetti, C. Tomasi, P. Calzavara-Pinton
Summary: This study aims to investigate the impact of pemphigus on sexual activity as well as its overall effect on quality of life.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Kamran Balighi, Cheida Shams-Davatchi, Salar Ghobadi, Maryam Daneshpazhooh, Vahide Lajevardi, Hamidreza Mahmoudi, Zeinab Aryanian, Amir Teymourpour, Ramtin Seirafi, Fereshteh Beigmohammadi, Soheil Tavakolpour
Summary: A retrospective study identified a subset of pemphigus patients with active lesions confined to the gingiva, who showed poor response to conventional treatments and rituximab therapy. Further studies on the pathogenesis of gingiva-confined presentation of pemphigus are needed.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Adi Nosrati, Tomer Mimouni, Emmilia Hodak, Michael Gdalevich, Meital Oren-Shabtai, Assi Levi, Daniel Mimouni, Yael A. Leshem
Summary: Rituximab is the first-line therapy for pemphigus disease, but relapse rates are high. Delayed use of rituximab is associated with decreased remission rates and early relapse. Early initiation of rituximab following diagnosis is recommended, and the effectiveness of maintenance therapy should be further investigated for severe patients.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Sang Gyun Lee, Soo-Chan Kim, Jong Hoon Kim
Summary: This retrospective study analyzed the risk factors for rituximab-induced thrombocytopenia (RIT) in patients with autoimmune bullous diseases (AIBDs). The study identified age and chronic kidney disease (CKD) as significant risk factors for RIT. Patients treated with the lymphoma protocol had a lesser reduction in post-rituximab platelet count compared to those on the rheumatoid arthritis (RA) protocol.
JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Adi Nosrati, Emmilia Hodak, Tomer Mimouni, Meital Oren-Shabtai, Assi Levi, Yael A. Leshem, Daniel Mimouni
Summary: A combination of rituximab and corticosteroids shows efficacy in inducing remission in most pemphigus patients in real-life settings, with certain patients experiencing relapses. Repeating treatment for relapsed patients can increase remission rates, with adverse events similar to previous studies.
Article
Dermatology
Il Joo Kwon, Taehee Kim, Dae San Yoo, Seoyeon Min, Soo-Chan Kim, Jong Hoon Kim
Summary: A retrospective study found that the combination therapy of rituximab and omalizumab can achieve disease control faster and reduce the required dose of corticosteroids in patients with refractory bullous pemphigoid.
JOURNAL OF DERMATOLOGY
(2023)
Review
Immunology
Mattie Rosi-Schumacher, John Baker, James Waris, Kristina Seiffert-Sinha, Animesh A. Sinha
Summary: Autoimmune blistering diseases such as bullous pemphigoid and pemphigus vulgaris are complex and multifactorial diseases with uncertain pathogenesis. Research on the epidemiologic risk factors of these diseases is hindered by their rare status and lack of centralized and standardized data.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Dermatology
Qiang Chen, Bin Hu, Li Wan, Lei Hu, Xiaoyong Zhou, Liuqing Chen, Jinbo Chen
Summary: Three cases of refractory bullous pemphigoid were successfully treated with ultra-low-dose rituximab (100 mg weekly for 4 weeks), confirming its efficacy and positive outcomes. The ultra-low-dose rituximab regimen may serve as a useful alternative therapy for refractory bullous pemphigoid patients.
JOURNAL OF DERMATOLOGY
(2023)
Article
Immunology
Siji Chen, Shaowei Zhan, Chunting Hua, Yi Tang, Hao Cheng
Summary: In this study, a patient with refractory pemphigus vulgaris and pulmonary tuberculosis was successfully treated with dupilumab for 10 weeks, resulting in improved skin lesions. RNA sequencing analysis of peripheral blood mononuclear cells showed downregulation of inflammatory response-related genes and IL-17 signaling pathway-related genes after treatment, suggesting the potential beneficial effect of dupilumab in aggressive refractory pemphigus vulgaris.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Meital Oren-Shabtai, Daniel Mimouni, Adi Nosrati, Lihi Atzmony, Baruch Kaplan, Aviv Barzilai, Sharon Baum
Summary: This study describes the clinical and immunological features of patients with recalcitrant BP treated with immunobiological therapies. The results show that the use of biological treatment can significantly improve the condition of BP patients and has no adverse events.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Ahreum Song, Jieun Jang, Ayeong Lee, Seo Yeon Min, Sang Gyun Lee, Soo-Chan Kim, Jaeyong Shin, Jong Hoon Kim
Summary: The study found that the reimbursement policy for rituximab in South Korea decreased the time to initiate treatment and the corticosteroid use for pemphigus patients. Additionally, the frequency of circulating desmoglein-specific atypical memory B cells can serve as a surrogate marker for a good prognosis after rituximab therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Shan Cao, Xiaochen Cui, Jianke Li, Futang Pan, Xiaoxiao Yan, Qing Yang, Mingfei Chen, Shengji Zhou, Donghong Du, Weiwei Wang, Yuanhang Sun, Zhongxiang Shi, Mei Wu, Baoqi Yang, Furen Zhang
Summary: This study investigated nail changes in patients with pemphigus and bullous pemphigoid and compared them with a control group. The results showed that nail changes were frequently observed in patients with these diseases, and the type and onset time of the changes may indicate the severity of the diseases. Nail changes could be a potential marker for disease progression.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Maria Efenesia Baffa, Alberto Corra, Roberto Maglie, Elena Biancamaria Mariotti, Francesca Montefusco, Carlo Pipito, Stefano Senatore, Lavinia Quintarelli, Marzia Caproni, Emiliano Antiga
Summary: This study evaluated a case series of patients with mucous membrane pemphigoid (MMP) treated with RTX. The results showed that adding RTX to conventional therapies can safely and effectively achieve rapid disease control in the majority of refractory MMP patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Zeinab Aryanian, Azar Shirzadian, Parvaneh Hatami, Gholam Abbas Roostayi, Sadrollah Najafi, Azadeh Goodarzi
Summary: This study evaluated the prevalence of ocular manifestations in Iranian patients with psoriasis and found that meibomian gland dysfunction was more common among patients. The study also found that intraocular pressure was slightly lower in patients compared to healthy controls. Furthermore, a positive correlation was observed between PASI values and tear meniscus height.
JOURNAL OF GENERAL AND FAMILY MEDICINE
(2023)
Letter
Dermatology
Zeinab Aryanian, Keyhan Omidi, Hamidreza Mahmoudi, Yousef Fakour, Ifa Etesami, Azadeh Goodarzi, Parvaneh Hatami
JOURNAL OF COSMETIC DERMATOLOGY
(2023)
Article
Dermatology
Pedram Nourmohammadpour, Amir Houshang Ehsani, Parvaneh Hatami, Saeed Aref, Zeinab Aryanian, Azadeh Goodarzi
Summary: This study evaluated the safety and efficacy of 1540 nm non-ablative fractional laser treatment in Iranian women with striae gravidarum (SG). The results showed that treatment with this laser may be considered a safe and partially effective option for SG patients, with minimal side effects.
JOURNAL OF COSMETIC AND LASER THERAPY
(2023)
Review
Dermatology
Parvaneh Hatami, Kamran Balighi, Hamed Nicknam Asl, Azadeh Goodarzi, Zeinab Aryanian
Summary: For decades, it has been widely accepted to postpone elective surgeries in patients on, or recently administered with isotretinoin. However, recent studies have shown the need for a change in this practice. We reviewed the existing data and summarized recommendations regarding the timing of procedural interventions in these patients. It is particularly important to follow stricter guidelines for patients with darker skin phototypes.
JOURNAL OF COSMETIC DERMATOLOGY
(2023)
Review
Dermatology
Zeinab Aryanian, Kamran Balighi, Parvaneh Hatami, Azadeh Goodarzi, Alireza Janbakhsh, Zeinab Mohseni Afshar
Summary: This article discusses the relationship between COVID-19 and vitiligo, as well as the impact of vaccines on vitiligo. It recommends that patients with vitiligo receive vaccines and consult dermatologists for medication adjustments.
JOURNAL OF COSMETIC DERMATOLOGY
(2023)
Article
Oncology
Kamran Balighi, Maryam Ghiasi, Zeinab Aryanian, Zahra Nikyar, Parvaneh Hatami
Summary: This article describes a case of Kaposi's sarcoma in a patient with pemphigus vulgaris who was receiving immunosuppressive therapy, highlighting the importance of considering other potential complications during diagnosis.
Editorial Material
Dermatology
Zeinab Aryanian, Kamran Balighi, Seyed Naser Emadi, Parvaneh Hatami
JOURNAL OF COSMETIC DERMATOLOGY
(2023)
Letter
Dermatology
Parvaneh Hatami, Zeinab Aryanian, Hamed Nicknam Asl, Azadeh Goodarzi, Dorsa Hatami
JOURNAL OF COSMETIC DERMATOLOGY
(2023)
Article
Dermatology
Zeinab Aryanian, Kamran Balighi, Baseerat Sajad, Nafiseh Esmaeli, Maryam Daneshpazhooh, Nasim Mazloumi Tootoonchi, Fereshteh Beigmohammadi, Zeinab Mohseni Afshar, Parvaneh Hatami
Summary: This retrospective study on 36 COVID-19 patients with pemphigus vulgaris found that the use of rituximab for treatment did not increase the risk of severe COVID-19. Most patients did not experience significant changes in pemphigus due to COVID-19.
JOURNAL OF COSMETIC DERMATOLOGY
(2023)
Review
Microbiology
Zeinab Mohseni Afshar, Azadeh Goodarzi, Seyed Naser Emadi, Ronak Miladi, Safoura Shakoei, Alireza Janbakhsh, Zeinab Aryanian, Parvaneh Hatami
Summary: This review characterizes the different dermatologic presentations in HIV-infected patients, including mucocutaneous signs and symptoms, etiopathogenic factors, and clinical management. The study provides a classification of HIV-related skin conditions, which can help clinicians understand the specific and nonspecific features of AIDS-associated cutaneous manifestations and manage them effectively.
INTERNATIONAL JOURNAL OF MICROBIOLOGY
(2023)
Article
Oncology
Kamran Balighi, Zeinab Aryanian, Shadi Balighi, Ifa Etesami, Parvaneh Hatami
Summary: The coexistence of esophageal squamous cell carcinoma and pemphigus vulgaris has been reported. In patients with pemphigus vulgaris, symptoms of dyspepsia and dysphagia may indicate the presence of more serious conditions other than pemphigus erosions.
Review
Oncology
Zeinab Aryanian, Kamran Balighi, Azadeh Goodarzi, Ali Sadeghi Nia, Zeinab Mohseni Afshar, Parvaneh Hatami
Summary: The SARS-CoV-2 pandemic has led to adaptations in dermatology practice, with certain diagnostic and therapeutic programs being suspended. The number of diagnosed skin cancers has significantly decreased, particularly during peaks of SARS-CoV-2 variants. Guidelines now allow for a 3-month delay in excision and recommend surgery for non-melanoma growing skin cancers. Dermatologists should conduct individualized risk-benefit assessments and consider changes in routine protocols.
Article
Medicine, General & Internal
Zeinab Aryanian, Kamran Balighi, Fatameh Mohaghegh, Ifa Etesami, Zahra Razavi, Parvaneh Hatami
Summary: More attention should be paid to cutaneous leishmaniasis in endemic regions, as it can mimic other dermatoses. Treatment should be initiated based on strong clinical suspicion, even without histopathologic or PCR confirmation, to prevent disfigurement or development of secondary malignancy.
CLINICAL CASE REPORTS
(2023)
Article
Medicine, General & Internal
Zeinab Aryanian, Insha Zainab Riyaz, Kamran Balighi, Ali Ahmadzade, Hamid Reza Mahmoudi, Arghavan Azizpour, Parvaneh Hatami
Summary: This study evaluated the efficacy and safety of using a combination treatment of mycophenolate mofetil or dapsone and methotrexate in pemphigus patients who had no response, exacerbation, or allergic reactions to rituximab therapy. The study found that male patients with high BMI who had an initial poor response to rituximab and subsequently received rituximab again had the highest number of relapses and benefited the most from this combination immunosuppressive treatment. Adjuvant immunosuppressant therapy may reduce the risk of relapse and improve the chance of remission.
CLINICAL CASE REPORTS
(2023)
Letter
Dermatology
Parvaneh Hatami, Zeinab Aryanian, Hamed Nicknam Asl, Azadeh Goodarzi, Azadeh Khayyat, Dorsa Hatami
JOURNAL OF COSMETIC DERMATOLOGY
(2023)